Delving into the Latest Updates on Serabelisib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

6-(2-Aminobenzo[d]oxazol-5-yl)imidazo [1,2-a]pyridine-3-yl morpholinomethanone, MLN1117, AGN-PC-0DB6FL

+ [5]

Target

PI3Kα

Mechanism

PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases+ [1]

Active Indication

Recurrent Endometrial CancerMetastatic Triple-Negative Breast CarcinomaAdvanced Malignant Solid Neoplasm+ [2]

Inactive Indication

Advanced cancerColorectal CancerHead and Neck Neoplasms+ [8]

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Faeth Therapeutics, Inc.Startup

University HospitalTakeda Pharmaceuticals International, Inc.

+ [3]

Inactive Organization

Millennium Pharmaceuticals, Inc.

Petra Pharma Corp.Startup

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC19H17N5O3

InChIKeyBLGWHBSBBJNKJO-UHFFFAOYSA-N

CAS Registry1268454-23-4

Author: Faller, Douglas V ; Han, Sileny N ; Makker, Vicky ; Jewell, Andrea ; Wenham, Robert M ; Alía, Eva María Guerra ; Sedarati, Farhad ; Vincent, Sylvie ; Raspagliesi, Francesco ; Neuwirth, Rachel ; Krell, Jonathan ; Baurain, Jean-François ; Braicu, Elena Ioana ; Su, Zhenqiang ; Oza, Amit ; Oaknin, Ana ; Scambia, Giovanni ; Colombo, Nicoletta

OBJECTIVE:

This phase 2 study investigated sapanisertib (selective dual inhibitor of mTORC1/2) alone, or in combination with paclitaxel or TAK-117 (a selective small molecule inhibitor of PI3K), versus paclitaxel alone in advanced, recurrent, or persistent endometrial cancer.

METHODS:

Patients with histologic diagnosis of endometrial cancer (1-2 prior regimens) were randomized to 28-day cycles on four treatment arms: 1) weekly paclitaxel 80 mg/m² (days 1, 8, and 15); 2) weekly paclitaxel 80 mg/m² + oral sapanisertib 4 mg on days 2-4, 9-11, 16-18, and 23-25; 3) weekly sapanisertib 30 mg, or 4) sapanisertib 4 mg + TAK-117 200 mg on days 1-3, 8-10, 15-17, and 22-24.

RESULTS:

Of 241 patients randomized, 234 received treatment (paclitaxel, n = 87 [3 ongoing]; paclitaxel+sapanisertib, n = 86 [3 ongoing]; sapanisertib, n = 41; sapanisertib+TAK-117, n = 20). The sapanisertib and sapanisertib+TAK-117 arms were closed to enrollment after futility analyses. After a median follow-up of 14.4 (paclitaxel) versus 17.2 (paclitaxel+sapanisertib) months, median progression-free survival (PFS; primary endpoint) was 3.7 versus 5.6 months (hazard ratio [HR] 0.82; 95% confidence interval [CI] 0.58-1.15; p = 0.139); in patients with endometrioid histology (n = 116), median PFS was 3.3 versus 5.7 months (HR 0.66; 95% CI 0.43-1.03). Grade ≥ 3 treatment-emergent adverse event rates were 54.0% with paclitaxel versus 89.5% paclitaxel+sapanisertib.

CONCLUSIONS:

Our findings support inclusion of chemotherapy combinations with investigational agents for advanced or metastatic disease. The primary endpoint was not met and toxicity was manageable.

TRIAL REGISTRATION:

ClinicalTrials.gov number, NCT02725268.

01 Nov 2023·European journal of medicinal chemistry

Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs

Article

Author: Chen, Yuan-Si ; Lei, Li ; Ban, Yu-Juan ; Zheng, Xue-Mei ; Tang, Lei ; Zhang, Ji-Quan ; Wang, Yu-Jie ; Li, Hong-Liang ; Guo, Bing ; Wang, Jian-Ta ; Dong, Yong-Xi

The dysregulation of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin signaling pathway has been implicated in various human cancers, and isoform-selective inhibitors targeting PI3Kα have received significant interest in recent years. In this study, we have designed and synthesized three series of substituted benzoxazole derivatives based on the clinical candidate TAK-117 (8a). A detailed structure-activity relationship (SAR) study has identified the optimal compound 18a bearing a quinoxaline scaffold. Compared to the control 8a, 18a exhibited 4.4-fold more potent inhibitory activity against PI3Kα (IC₅₀: 2.5 vs 11 nM) and better isoform-selective profiles over other PI3Ks. In addition, 18a showed a 1.5-fold more potent antiproliferative effect against HCT-116 cell lines (IC₅₀: 3.79 vs 5.80 μM) and a better selectivity over the normal tissue cells. The potential antitumor mechanism and in vitro metabolic stability of 18a were also investigated. Notably, pharmacokinetic assays indicated that 18a had a higher plasma exposure, a higher maximum concentration and shorter elimination time compared to 8a.

09 Dec 2022·The oncologist

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Article

Author: Powles, Thomas ; Duran, Ignacio ; Sedarati, Farhad ; Suárez, Cristina ; Hainsworth, John ; Reeves, James ; Voog, Eric ; Chen, Jingjing ; Castellano, Daniel ; Czaykowski, Piotr ; Choueiri, Toni K ; Porta, Camillo

Abstract:

Background:

Sapanisertib, a dual mTORC1/2 inhibitor, may offer more complete inhibition of the PI3K/AKT/mTOR pathway than mTORC1 inhibitors, such as everolimus. This phase II study evaluated the efficacy and safety of single-agent sapanisertib and sapanisertib plus the PI3Kα inhibitor TAK-117, vs. everolimus in patients with advanced clear cell renal cell carcinoma (ccRCC) that had progressed on or after VEGF-targeted therapy.

Materials and Methods:

Patients with histologically confirmed, advanced ccRCC were randomized 1:1:1 to receive single-agent everolimus 10 mg once daily, single-agent sapanisertib 30 mg once weekly, or sapanisertib 4 mg plus TAK-117 200 mg, both once daily for 3 days/week, in 28-day cycles. The primary endpoint was progression-free survival (PFS).

Results:

Ninety-five patients were treated with everolimus or sapanisertib (n = 32 each), or sapanisertib plus TAK-117 (n = 31). There were no significant differences in PFS among the 3 groups or across any subgroups. Median PFS was 3.8 months with everolimus vs. 3.6 months with sapanisertib (HR, 1.33; 95% CI, 0.75-2.36), and 3.1 months with sapanisertib plus TAK-117 (HR, 1.37; 95% CI, 0.75-2.52). No significant differences in overall survival were seen among groups. Overall response rate was 16.7%, 0%, and 7.1%, respectively. Discontinuations due to treatment-emergent adverse events were 15.6%, 28.1%, and 29.0%.

Conclusion:

Sapanisertib with or without TAK-117 was less tolerable and did not improve efficacy vs. everolimus in patients with advanced ccRCC who had relapsed after or were refractory to VEGF-targeted therapies. Dual mTORC1/2 inhibition may not be an effective therapeutic approach for these patients.

2

News (Medical) associated with Serabelisib

30 May 2024

·www.biospace.com

Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference

Faeth’s CEO to showcase how AI has unlocked metabolism as a new cancer treatment paradigm AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, (Faeth) a clinical-stage biotechnology company, announced today that Anand Parikh, Chief Executive Officer (CEO), will participate in one-on-one investor meetings at the upcoming Jefferies Global Healthcare Conference being held June 4-6 in New York. To schedule a meeting at the conference with Faeth’s CEO, please contact bridie@faeththerapeutics.com. For more information about the conference, please contact your institutional sales representative at Jefferies. Founded by renowned oncology researchers including Drs. Lew Cantley, Siddhartha Mukherjee, and Karen Vousden alongside CEO Anand Parikh, Faeth is focused on developing therapies targeting cancer metabolism. The role of metabolism in cancer proliferation is well established, yet remains a vastly under-exploited area, with very few cancer metabolism therapies in existence today. Faeth’s differentiated approach to targeting cancer metabolism leverages a systemic understanding of cancer metabolism, functional genomics, and computational biology to develop effective, less toxic therapies. Faeth has a robust clinical and preclinical pipeline driven by the company’s MetabOS discovery platform, which leverages AI, machine learning, and curated data sets to identify targets matched to specific tumor genotypes. Faeth's lead program, FTH-001/003, or "PIKTOR," includes serabelisib, a PI3Kɑ inhibitor, and sapanisertib, an mTORC 1/2 inhibitor, which together effectively shut down the PI3K pathway, the most commonly mutated pathway in cancer. PIKTOR, together with paclitaxel, has already shown outstanding results in a Phase 1b trial including endometrial, ovarian, and breast cancers. Faeth's second clinical program features FTH-002, a specially formulated amino acid sachet, which is administered in conjunction with an amino acid-restricted regimen and radio/chemotherapy. About Faeth Therapeutics Faeth Therapeutics is a clinical-stage biotechnology company at the forefront of oncology research with a robust clinical and preclinical pipeline powered by its AI-driven MetabOS discovery platform. Faeth’s lead program, PIKTOR, has shown outstanding clinical results in a Phase 1b trial and is advancing into a Phase 2 trial in endometrial cancer in 2024. For additional information, visit .

Phase 1Phase 2Clinical Result

08 Nov 2023

·www.biospace.com

Faeth Therapeutics to Participate in the Stifel 2023 Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, an oncology company with clinical programs combining therapeutics with metabolic optimization to achieve greater efficacy, today announced that the company will be participating in a company presentation and 1x1 investor meetings at the Stifel 2023 Healthcare Conference, taking place from November 14-15 in New York City. Anand Parikh, J.D., Chief Executive Officer & Co-Founder, Oliver Maddocks, PhD, Head of Research & Co-Founder, and Debbie Chirnomas, MD, Chief Medical Officer, will present a company overview on Wednesday, November 15, at 3:00 pm ET. About Faeth Therapeutics Faeth Therapeutics, headquartered in Austin, TX, is a clinical-stage biotechnology company focused on bringing breakthrough research in metabolic oncology into the clinic. The company leverages its machine-learning platform to develop precision therapies, augmented by a metabolic regimen involving the patient’s diet, to revolutionize the treatment paradigm. Faeth’s lead program combines FTH-001, serabelisib, with FTH-003, sapanisertib, and an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/mTOR pathway. Faeth’s scientific founders include industry leaders Drs. Lew Cantley, Sid Mukherjee, Karen Vousden. For additional information, visit .

100 Deals associated with Serabelisib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14935

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
Colorectal Cancer	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
Endometrial Carcinoma	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
Head and Neck Neoplasms	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
Lung Cancer	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
PIK3CA H1047R mutant Breast Cancer	Phase 2	-	Petra Pharma Corp.Startup	01 Sep 2020
Metastatic Triple-Negative Breast Carcinoma	Phase 2	US	Takeda Pharmaceutical Co., Ltd.	18 Jul 2017
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	US	Millennium Pharmaceuticals, Inc.	30 Jun 2016
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	CA	Millennium Pharmaceuticals, Inc.	30 Jun 2016
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	CZ	Millennium Pharmaceuticals, Inc.	30 Jun 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03154294 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	19	paclitaxel+TAK-117+TAK-228 (Cohort 1)	kylmskvivx(fzlygucyrr) = qubxuilhma hgcusonmey (ddctegeuqw, varpdosnxk - vvdhoxoijh) View more	-	26 Jul 2024
				paclitaxel+TAK-117+TAK-228 (Cohort 2)	kylmskvivx(fzlygucyrr) = xnmtvcuzjb hgcusonmey (ddctegeuqw, wgogyodmlt - lyvcicomlx) View more
NCT03193853 (CTgov)	Phase 2	Metastatic Triple-Negative Breast Carcinoma	12	Nab Paclitaxel+Cisplatin+Tak-117+Tak-228	agpauvqnnc(biiaxhijqp) = zgrccpiiwr kehyfqbdyk (vtvzeprmhs, ljgvcejpjw - wnbnbxzvym) View more	-	09 May 2023
NCT03154294 (ASCO2021) Manual	Phase 1	Ovarian Cancer \| Endometrial Carcinoma \| Breast Cancer PI3K Mutation \| AKT Mutation \| MTOR Mutation	19	paclitaxel+sapanisertib+serabelisib	xcixaupohr(nhjzlknjlu) = seljbgcgki rhmfzbtcku (wwpbabhfzu ) View more	Positive	20 May 2021
NCT02725268 (phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer, CTgov)	Phase 2	Recurrent Endometrial Cancer	241	Paclitaxel (Paclitaxel 80 mg/m^2)	uitmlmkcrf(ieimoyqlaj) = byotklutng avphdtnebx (golzxiuafr, zhdrkwizhz - drzosrxzrb) View more	-	09 Jun 2020
				Paclitaxel+Sapanisertib (Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg)	uitmlmkcrf(ieimoyqlaj) = oboixlvskx avphdtnebx (golzxiuafr, eturfcyfrg - givhcyzbmn) View more
NCT01449370 (ASCO2015)	Phase 1	Advanced Malignant Solid Neoplasm	76	MLN1117 once daily (QD)	gdvgyydpsh(fciatoryyh) = zanttjwgjt ihbvyhhkjy (lemwjkbstd ) View more	-	20 May 2015
				MLN1117 3 days per week (MWF)	gdvgyydpsh(fciatoryyh) = sgaebrtzaz ihbvyhhkjy (lemwjkbstd ) View more